Blackstone Inc. Boosts Stock Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Blackstone Inc. grew its position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 40.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 913,060 shares of the company's stock after buying an additional 263,060 shares during the quarter. Blackstone Inc. owned 1.68% of Bicara Therapeutics worth $15,906,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC purchased a new stake in Bicara Therapeutics during the third quarter valued at approximately $1,239,000. JPMorgan Chase & Co. grew its position in shares of Bicara Therapeutics by 8,768.5% during the 4th quarter. JPMorgan Chase & Co. now owns 64,740 shares of the company's stock valued at $1,128,000 after acquiring an additional 64,010 shares during the period. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics in the 4th quarter worth $33,000. Barclays PLC bought a new position in Bicara Therapeutics in the 3rd quarter worth $255,000. Finally, Bank of New York Mellon Corp purchased a new position in Bicara Therapeutics during the fourth quarter valued at $701,000.

Bicara Therapeutics Stock Down 1.8 %

Shares of BCAX traded down $0.23 during midday trading on Friday, hitting $12.90. 729,786 shares of the company traded hands, compared to its average volume of 487,077. The firm has a 50 day moving average of $12.95 and a 200-day moving average of $15.61. Bicara Therapeutics Inc. has a 52 week low of $8.91 and a 52 week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). Analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Wedbush reaffirmed an "outperform" rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. HC Wainwright reduced their price objective on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a research note on Monday, April 7th. Finally, Wells Fargo & Company began coverage on shares of Bicara Therapeutics in a research note on Thursday, April 17th. They set an "underweight" rating and a $8.00 target price on the stock. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.43.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.